Catalys Pacific

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease. The company primarily aims to address the unmet medical need associated with secondary hyperparathyroidism (SHPT), a condition characterized by the overactivity of the parathyroid glands due to external diseases. Pathalys is developing upacicalcet, a novel calcimimetic designed to improve SHPT treatment in patients undergoing hemodialysis. Upacicalcet works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor found in various human organs. This approach has the potential to enhance patient care for those suffering from end-stage chronic kidney disease.

Arialys Therapeutics is a pre-clinical stage biotechnology company that specializes in neuroscience, particularly in the development of precision medicines aimed at blocking pathogenic autoantibodies in the brain. The company investigates the role of the immune system in central nervous system (CNS) health and disease, focusing on the characterization and prevalence of pathogenic auto-antibody activity. Arialys Therapeutics aims to provide advanced therapies for various CNS disorders, including neuropsychiatric conditions linked to autoimmune diseases, thereby contributing to the healthcare industry's efforts to address complex neurological challenges.

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease. The company primarily aims to address the unmet medical need associated with secondary hyperparathyroidism (SHPT), a condition characterized by the overactivity of the parathyroid glands due to external diseases. Pathalys is developing upacicalcet, a novel calcimimetic designed to improve SHPT treatment in patients undergoing hemodialysis. Upacicalcet works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor found in various human organs. This approach has the potential to enhance patient care for those suffering from end-stage chronic kidney disease.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

HilleVax is a clinical-stage biopharmaceutical company established in 2021 and based in Boston, Massachusetts. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a vaccine candidate that utilizes virus-like particle (VLP) technology aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.

Pathalys Pharma is a clinical biopharmaceutical company focused on developing innovative therapeutics for late-stage chronic kidney disease. The company primarily aims to address the unmet medical need associated with secondary hyperparathyroidism (SHPT), a condition characterized by the overactivity of the parathyroid glands due to external diseases. Pathalys is developing upacicalcet, a novel calcimimetic designed to improve SHPT treatment in patients undergoing hemodialysis. Upacicalcet works by mimicking the action of calcium on tissues, activating the calcium-sensing receptor found in various human organs. This approach has the potential to enhance patient care for those suffering from end-stage chronic kidney disease.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Exalys Therapeutics is engaged in the development of innovative anti-inflammatory therapeutics aimed at addressing a variety of diseases that currently have significant unmet medical needs. The company is focusing on creating first-in-class therapies, with an initial emphasis on preventing postoperative delirium, a common complication among older surgical patients that can lead to adverse health outcomes. By targeting inflammatory disorders, including pain and renal dysfunction, Exalys aims to provide effective treatment options for conditions that are often serious and life-threatening, yet lack adequate therapies.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.